(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 89.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Geron's revenue in 2025 is $76,994,000.On average, 5 Wall Street analysts forecast GERN's revenue for 2025 to be $139,845,114,478, with the lowest GERN revenue forecast at $133,546,129,270, and the highest GERN revenue forecast at $148,118,503,543. On average, 5 Wall Street analysts forecast GERN's revenue for 2026 to be $220,260,672,860, with the lowest GERN revenue forecast at $169,365,636,662, and the highest GERN revenue forecast at $265,984,044,761.
In 2027, GERN is forecast to generate $342,840,580,965 in revenue, with the lowest revenue forecast at $226,445,015,264 and the highest revenue forecast at $453,635,208,758.